Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform

References

• Reichert JM. Antibodies to watch in 2014. MAbs 2013; 6:6; PMID: 24284914
   PubMedGoogle Scholar
• Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, et al. Rise and fall of an anti-MUC1 specific antibody. PLoS One 2011; 6:e15921; http://dx.doi.org/10.1371/journal.pone.0015921; PMID: 21264246
   PubMed Web of Science ®Google Scholar
• Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 2011; 6:e21018; http://dx.doi.org/10.1371/journal.pone.0021018; PMID: 21698301
   PubMed Web of Science ®Google Scholar
• Muirhead M, Martin PJ, Torok-Storb B, Uhr JW, Vitetta ES. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 1983; 62:327 - 32; PMID: 6409188
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406 - 13; http://dx.doi.org/10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U; PMID: 11466696
   PubMed Web of Science ®Google Scholar
• Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000; 6:1302 - 13; PMID: 10778955
   PubMed Web of Science ®Google Scholar
• Rybak SM, Arndt MAE, Schirrmann T, Dübel S, Krauss J. Ribonucleases and immunoRNases as anticancer drugs. Curr Pharm Des 2009; 15:2665 - 75; http://dx.doi.org/10.2174/138161209788923921; PMID: 19689337
   PubMed Web of Science ®Google Scholar
• Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem 1991; 266:21202 - 7; PMID: 1939162
   PubMed Web of Science ®Google Scholar
• Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274 - 81; http://dx.doi.org/10.1200/JCO.20.1.274; PMID: 11773179
   PubMed Web of Science ®Google Scholar
• Benito A, Ribó M, Vilanova M. On the track of antitumour ribonucleases. Mol Biosyst 2005; 1:294 - 302; http://dx.doi.org/10.1039/b502847g; PMID: 16880994
   PubMed Web of Science ®Google Scholar
• Lee I. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 2008; 8:813 - 27; http://dx.doi.org/10.1517/14712598.8.6.813; PMID: 18476793
   PubMed Web of Science ®Google Scholar
• Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993; 268:10686 - 93; PMID: 8486718
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Krauss J, Arndt MAE, Rybak SM, Dübel S. Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 2009; 9:79 - 95; http://dx.doi.org/10.1517/14712590802631862; PMID: 19063695
   PubMed Web of Science ®Google Scholar
• Krauss J, Arndt MAE, Vu BK, Newton DL, Seeber S, Rybak SM. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. Biochem Biophys Res Commun 2005; 331:595 - 602; http://dx.doi.org/10.1016/j.bbrc.2005.03.215; PMID: 15850802
   PubMed Web of Science ®Google Scholar
• Beintema JJ, Kleineidam RG. The ribonuclease A superfamily: general discussion. Cell Mol Life Sci 1998; 54:825 - 32; http://dx.doi.org/10.1007/s000180050211; PMID: 9760991
   PubMed Web of Science ®Google Scholar
• Boix E, Nogués MV. Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence. Mol Biosyst 2007; 3:317 - 35; http://dx.doi.org/10.1039/b617527a; PMID: 17460791
   PubMed Web of Science ®Google Scholar
• D’Alessio G. New and cryptic biological messages from RNases. Trends Cell Biol 1993; 3:106 - 9; http://dx.doi.org/10.1016/0962-8924(93)90166-X; PMID: 14731764
   PubMedGoogle Scholar
• Yang D, Chen Q, Rosenberg HF, Rybak SM, Newton DL, Wang ZY, Fu Q, Tchernev VT, Wang M, Schweitzer B, et al. Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 2004; 173:6134 - 42; PMID: 15528350
   PubMed Web of Science ®Google Scholar
• Gupta SK, Haigh BJ, Griffin FJ, Wheeler TT. The mammalian secreted RNases: mechanisms of action in host defence. Innate Immun 2013; 19:86 - 97; http://dx.doi.org/10.1177/1753425912446955; PMID: 22627784
   PubMed Web of Science ®Google Scholar
• Borriello M, Laccetti P, Terrazzano G, D’Alessio G, De Lorenzo C. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer 2011; 104:1716 - 23; http://dx.doi.org/10.1038/bjc.2011.146; PMID: 21559015
   PubMed Web of Science ®Google Scholar
• Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61:8737 - 42; PMID: 11751393
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R, D’Alessio G. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 2004; 64:4870 - 4; http://dx.doi.org/10.1158/0008-5472.CAN-03-3717; PMID: 15256457
   PubMed Web of Science ®Google Scholar
• Menzel C, Schirrmann T, Konthur Z, Jostock T, Dübel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 2008; 111:3830 - 7; http://dx.doi.org/10.1182/blood-2007-04-082768; PMID: 18230757
   PubMed Web of Science ®Google Scholar
• Zewe M, Rybak SM, Dübel S, Coy JF, Welschof M, Newton DL, Little M. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997; 3:127 - 36; http://dx.doi.org/10.1016/S1380-2933(97)00070-5; PMID: 9237097
   PubMedGoogle Scholar
• Park C, Schultz LW, Raines RT. Contribution of the active site histidine residues of ribonuclease A to nucleic acid binding. Biochemistry 2001; 40:4949 - 56; http://dx.doi.org/10.1021/bi0100182; PMID: 11305910
   PubMed Web of Science ®Google Scholar
• Bal HP, Batra JK. Human pancreatic ribonuclease--deletion of the carboxyl-terminal EDST extension enhances ribonuclease activity and thermostability. Eur J Biochem 1997; 245:465 - 9; http://dx.doi.org/10.1111/j.1432-1033.1997.t01-1-00465.x; PMID: 9151980
   PubMedGoogle Scholar
• Johnson RJ, McCoy JG, Bingman CA, Phillips GN Jr., Raines RT. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 2007; 368:434 - 49; http://dx.doi.org/10.1016/j.jmb.2007.02.005; PMID: 17350650
   PubMed Web of Science ®Google Scholar
• Murthy BS, Sirdeshmukh R. Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. Biochem J 1992; 281:343 - 8; PMID: 1736883
   PubMed Web of Science ®Google Scholar
• Riccio G, Borriello M, D’Alessio G, De Lorenzo C. A novel human antitumor dimeric immunoRNase. J Immunother 2008; 31:440 - 5; http://dx.doi.org/10.1097/CJI.0b013e31816bc769; PMID: 18463541
   PubMed Web of Science ®Google Scholar
• Benito A, Bosch M, Torrent G, Ribó M, Vilanova M. Stabilization of human pancreatic ribonuclease through mutation at its N-terminal edge. Protein Eng 2002; 15:887 - 93; http://dx.doi.org/10.1093/protein/15.11.887; PMID: 12538908
   PubMedGoogle Scholar
• Turcotte RF, Lavis LD, Raines RT. Onconase cytotoxicity relies on the distribution of its positive charge. FEBS J 2009; 276:3846 - 57; http://dx.doi.org/10.1111/j.1742-4658.2009.07098.x; PMID: 19523116
   PubMed Web of Science ®Google Scholar
• Leland PA, Staniszewski KE, Kim B-M, Raines RT. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 2001; 276:43095 - 102; http://dx.doi.org/10.1074/jbc.M106636200; PMID: 11555655
   PubMed Web of Science ®Google Scholar
• Leland PA, Schultz LW, Kim B-M, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A 1998; 95:10407 - 12; http://dx.doi.org/10.1073/pnas.95.18.10407; PMID: 9724716
   PubMed Web of Science ®Google Scholar
• Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 8:603 - 12; http://dx.doi.org/10.1038/nrm2216; PMID: 17609668
   PubMed Web of Science ®Google Scholar
• Mayor S, Riezman H. Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol 2004; 5:110 - 20; http://dx.doi.org/10.1038/nrm1309; PMID: 15040444
   PubMed Web of Science ®Google Scholar
• Leich F, Stöhr N, Rietz A, Ulbrich-Hofmann R, Arnold U. Endocytotic internalization as a crucial factor for the cytotoxicity of ribonucleases. J Biol Chem 2007; 282:27640 - 6; http://dx.doi.org/10.1074/jbc.M702240200; PMID: 17635931
   PubMed Web of Science ®Google Scholar
• Notomista E, Mancheño JM, Crescenzi O, Di Donato A, Gavilanes J, D’Alessio G. The role of electrostatic interactions in the antitumor activity of dimeric RNases. FEBS J 2006; 273:3687 - 97; http://dx.doi.org/10.1111/j.1742-4658.2006.05373.x; PMID: 16911519
   PubMed Web of Science ®Google Scholar
• Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 2002; 13:855 - 69; http://dx.doi.org/10.1021/bc025536j; PMID: 12121142
   PubMed Web of Science ®Google Scholar
• Harada M, Sakakibara H, Yano T, Suzuki T, Okuno S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 2000; 69:399 - 412; http://dx.doi.org/10.1016/S0168-3659(00)00321-7; PMID: 11102680
   PubMed Web of Science ®Google Scholar
• Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, et al, Cancer Research Campaign Phase I/II Committee. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999; 5:83 - 94; PMID: 9918206
   PubMed Web of Science ®Google Scholar
• Mathieu MA, Bogyo M, Caffrey CR, Choe Y, Lee J, Chapman H, Sajid M, Craik CS, McKerrow JH. Substrate specificity of schistosome versus human legumain determined by P1-P3 peptide libraries. Mol Biochem Parasitol 2002; 121:99 - 105; http://dx.doi.org/10.1016/S0166-6851(02)00026-9; PMID: 11985866
   PubMed Web of Science ®Google Scholar
• Schmid B, Chung D-E, Warnecke A, Fichtner I, Kratz F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 2007; 18:702 - 16; http://dx.doi.org/10.1021/bc0602735; PMID: 17378599
   PubMed Web of Science ®Google Scholar
• Erickson HA, Jund MD, Pennell CA. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. Protein Eng Des Sel 2006; 19:37 - 45; http://dx.doi.org/10.1093/protein/gzi073; PMID: 16243897
   PubMed Web of Science ®Google Scholar
• Schmid B, Warnecke A, Fichtner I, Jung M, Kratz F. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library. Bioconjug Chem 2007; 18:1786 - 99; http://dx.doi.org/10.1021/bc0700842; PMID: 17915955
   PubMed Web of Science ®Google Scholar
• Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stöcker M. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008; 31:370 - 6; http://dx.doi.org/10.1097/CJI.0b013e31816a2d23; PMID: 18391759
   PubMed Web of Science ®Google Scholar
• Gaur D, Swaminathan S, Batra JK. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. Generation of inhibitor-resistant cytotoxic variants. J Biol Chem 2001; 276:24978 - 84; http://dx.doi.org/10.1074/jbc.M102440200; PMID: 11342552
   PubMed Web of Science ®Google Scholar
• Wu Y, Saxena SK, Ardelt W, Gadina M, Mikulski SM, De Lorenzo C, D’Alessio G, Youle RJ. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem 1995; 270:17476 - 81; http://dx.doi.org/10.1074/jbc.270.29.17476; PMID: 7542240
   PubMed Web of Science ®Google Scholar
• Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 1997; 36:11051 - 4; http://dx.doi.org/10.1021/bi971383p; PMID: 9333321
   PubMed Web of Science ®Google Scholar
• Worthington ZEV, Carbonetti NH. Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect Immun 2007; 75:2946 - 53; http://dx.doi.org/10.1128/IAI.02011-06; PMID: 17420233
   PubMed Web of Science ®Google Scholar
• Mikulski SM, Viera A, Deptala A, Darzynkiewicz Z. Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. Int J Oncol 1998; 13:633 - 44; PMID: 9735389
   PubMed Web of Science ®Google Scholar
• Rodríguez M, Benito A, Tubert P, Castro J, Ribó M, Beaumelle B, Vilanova M. A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. J Mol Biol 2006; 360:548 - 57; http://dx.doi.org/10.1016/j.jmb.2006.05.048; PMID: 16780873
   PubMed Web of Science ®Google Scholar
• Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 2002; 277:15142 - 6; http://dx.doi.org/10.1074/jbc.M108115200; PMID: 11839736
   PubMed Web of Science ®Google Scholar
• Qiao M, Zu L-D, He X-H, Shen R-L, Wang Q-C, Liu M-F. Onconase downregulates microRNA expression through targeting microRNA precursors. Cell Res 2012; 22:1199 - 202; http://dx.doi.org/10.1038/cr.2012.67; PMID: 22525336
   PubMed Web of Science ®Google Scholar
• Torrent G, Ribó M, Benito A, Vilanova M. Bactericidal activity engineered on human pancreatic ribonuclease and onconase. Mol Pharm 2009; 6:531 - 42; http://dx.doi.org/10.1021/mp8001914; PMID: 19718804
   PubMed Web of Science ®Google Scholar
• Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H. Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 2001; 40:7518 - 24; http://dx.doi.org/10.1021/bi010248g; PMID: 11412105
   PubMed Web of Science ®Google Scholar
• Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30:E9; http://dx.doi.org/10.1093/nar/30.2.e9; PMID: 11788735
   PubMed Web of Science ®Google Scholar
• Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013; 13:52; http://dx.doi.org/10.1186/1472-6750-13-52; PMID: 23802841
   PubMed Web of Science ®Google Scholar
• Tom R, Bisson L, Durocher Y. Transient expression in HEK293-EBNA1 cells. In: Dyson MR, Durocher, Yves, editors. Expression Systems: Methods Express. Scion; 2007.
   Google Scholar
• Leland PA, Schultz LW, Kim B-M, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A 1998; 95:10407 - 12; http://dx.doi.org/10.1073/pnas.95.18.10407; PMID: 9724716
   PubMed Web of Science ®Google Scholar
• Kelemen BR, Klink TA, Behlke MA, Eubanks SR, Leland PA, Raines RT. Hypersensitive substrate for ribonucleases. Nucleic Acids Res 1999; 27:3696 - 701; http://dx.doi.org/10.1093/nar/27.18.3696; PMID: 10471739
   PubMed Web of Science ®Google Scholar